# Fluorescence QRH-882260 Peptide Imaging in the Bile Duct

> **NCT03438435** · PHASE1 · COMPLETED · sponsor: **D. Kim Turgeon, MD** · enrollment: 1 (actual)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **DRUG:** QRH-882260 Heptapeptide

## Key facts

- **NCT ID:** NCT03438435
- **Lead sponsor:** D. Kim Turgeon, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-22
- **Primary completion:** 2020-08-21
- **Final completion:** 2020-08-21
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2020-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03438435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03438435, "Fluorescence QRH-882260 Peptide Imaging in the Bile Duct". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03438435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*